Skip to main content

Switch Language

English
Spanish

Thrombosis Adviser

This website is intended to provide information to an international audience outside the USA and UK

I am a Healthcare Professional
I am a Patient

Thrombosis Adviser
for Healthcare Professionals
Knowledge Base
Essentials
Introduction
Haemostasis
The Coagulation Cascade
Introduction
Factor Xa Inhibitors
Direct Thrombin Inhibitors
Vitamin K Antagonists
Heparins

Thrombus Formation
Venous Thrombosis
Arterial Thrombosis

Stroke Prevention
Atrial Fibrillation-Related Stroke
Introduction to AF
Prevention
Preventing AF-Related Stroke
Patients with NVAF
Anticoagulant Therapy
Antiplatelet Therapy
Anticoagulation and Cardiac Procedures
Other Options
Patients with VAF
Pharmacological Therapy
Surgery

Special Populations
Older Patients with AF
Patients with AF and diabetes
Patients with AF undergoing PCI
Patients with Renal Impairment
Patients with Worsening Renal Function

Venous Thrombosis
Introduction
Prevention
Introduction
Anticoagulant Therapy for Venous Thromoembolism Prevention
Other Options

Deep Vein Thrombosis & Pulmonary Embolism
Deep VT Introduction and Diagnosis
Pulmonary Embolism Introduction and Diagnosis
Treatment

Extended Treatment
Complications
VTE in Special Populations
Patients with VTE and Renal Impairment
Paediatric VTE
Frail and Elderly Patients with VTE

Cancer-Associated Thrombosis
Introduction to Cancer-Associated Thrombosis
Treatment and Prevention of Recurrent Events

Arterial Thrombosis
Acute Coronary Syndrome
Introduction
Treatment
Secondary Prevention

Coronary Artery Disease (CAD)
Peripheral Artery Disease (PAD)

Glossary

Latest In Thrombosis
Thrombosis Digest
2022
ESC 2022 Congress Highlights
International Society on Thrombosis and Haemostasis (ISTH) Congress 2022 Newsletter
International Conference on Thrombosis and Hemostasis Issues in Cancer (ICTHIC) 2022
Your older patients with atrial fibrillation: Are you missing the broader picture?
EHRA 2022 Congress Highlights
Extended treatment for recurrent VTE: Protecting your patients for as long as they need
The use of NOACs in the extended management of cancer‑associated thrombosis
Protecting elderly patients with atrial fibrillation

2021
Preserving kidney function in patients with atrial fibrillation: What do the new data say?
Bayer symposium highlights from the ESC congress 2021
Protecting vulnerable patients with VTE: Choose a guideline-recommended therapy that has been thoroughly tested
Ensuring protection for patients with cancer-associated thrombosis
International Society on Thrombosis and Haemostasis Conference 2021 newsletter
Patient preference: How can it help to reduce the burden of thrombosis in patients with cancer-associated thrombosis?
Stroke prevention in older patients: How can you protect those who need it most?
International Conference on Thrombosis and Hemostasis Issues in Cancer 2021

2020
When is the right time to start thinking about renal function in patients with AF?
Thrombosis Adviser at the European Society of Cardiology Congress 2020
Extended Treatment for VTE: Tailoring Treatment for Patients Who Need it
Patients with diabetes and atrial fibrillation: How can the risk of cardiovascular death be reduced?
Managing anticoagulation during the COVID-19 pandemic
Supporting the treatment of patients with low-risk pulmonary embolism at home
The importance of real-world evidence: A look at stroke prevention in atrial fibrillation
Keeping it simple: Single drug approaches to VTE treatment
The importance of preserving kidney function in atrial fibrillation
Where next in cancer-associated thrombosis?
Time for a change? Switching anticoagulants in patients with AF or VTE
High-risk patients with atrial fibrillation: The importance of protection
Understanding the risk of VTE recurrence: Who needs extended anticoagulation?
ESC Heart and Stroke Conference: Highlights from Bayer 24–25 January 2020
Venous protection in 2019: A year in review
Stroke prevention in patients with AF in 2019: A year in review

2019
ThrombosisAdviser at the European Society of Cardiology Congress 2019
ThrombosisAdviser at the European Society of Cardiology Congress 2019: Focus on Atrial Fibrillation
PE ESC 2019 Guidelines
Paediatric patients with VTE: Protecting the most challenging population
VTE-CAT: Reducing the burden of injections
ISTH congress highlights from Bayer July 2019
Making connections: Stroke risk in patients with multiple co-morbidities
High-risk patients with atrial fibrillation: Spotlight on renal impairment
High-risk patients with atrial fibrillation: Spotlight on diabetes
VTE Treatment in Challenging Patient
Dosing Schemas of the NOACs for VTE Treatment
ESC Heart and Stroke Conference Highlights
Improving AF Detection

2018
Interpreting Safety Results of NOACs Based on Bleeding Risk
Managing the multi-morbid patient with AF: Focus on patients with renal impairment
Challenges in Interpreting Real-World Studies Involving the NOACs
Residual MACE in CAD: What Are the Long-Term Adverse Cardiac Events to Worry About?

Real-World Evidence
Introduction
AF Real-World Studies
ACS Real-World Studies
VTE Real-World Studies

Tools and Resources
Which Anticoagulant?
Image Library
Audio Library
Video Library
Timelines
Anticoagulant Timeline
Stroke Prevention
Atrial fibrillation: A patient’s journey
OACs Timeline
Stroke Risk Evaluation Timeline

Venous Protection
Treatment of VTE Timeline
VTE: A patient’s journey

COVID-19 Patient Checklist
Vascular Adviser
for Healthcare Professionals
for Patients and Carers

Toggle Search

Toggle Search

Vascular Adviser
For Patients and Carers
Knowledge Base
Latest in Thrombosis
- Thrombosis Digest
- Real-World Evidence
Tools and Resources
Newsletter Subscribe Form

Country select
- Country 1
- Country 2

Switch Language

English
Spanish

Thrombosis Adviser
for Healthcare Professionals

Tools and Resources

Which Anticoagulant?
Image Library
Audio Library
- Venous Thromboembolism Audio Library
- Prevention of stroke in patients with atrial fibrillation and comorbidities Audio Library
Video Library

Join more than 1.500 of your peers to stay up to date with the latest in thrombosis.

Sign up now!

Subscribe

See Also

Peripheral Artery Disease: causes and consequences

Coronary Artery Disease: causes and consequences

Peripheral Artery Disease: causes and consequences

Peripheral Artery Disease: causes and consequences

Coronary Artery Disease: causes and consequences

Coronary Artery Disease: causes and consequences

Breadcrumb

Video Library

Video Library

Filter by Topic:

All
Atrial Fibrillation
Arterial Thrombosis
Coagulation Cascade
Coronary Artery Disease and Peripheral Artery Disease
VTE

Videos filtered by:

Rivaroxaban-Treated AF Patients with Prior Stroke and TIA Confirming RCT Data in the Real World

Rivaroxaban-Treated AF Patients with Prior Stroke and TIA Confirming RCT Data in the Real World

Prof. Danilo Toni discusses findings from the RE-AFFIRM study for patients with prior stroke treated with Rivaroxaban vs. Warfarin in clinical routine and puts the data from the randomized controlled trial ROCKET AF into perspective

© Bayer AG, 2020 | Approval number PP-XAR-ALL-1767-1

PIONEER AF-PCI trial overview

PIONEER AF-PCI trial overview

Overview of the PIONEER AF-PCI trial assessing the safety and efficacy of rivaroxaban compared with a VKA in patients with AF undergoing PCI

© Bayer AG, 2020 | Approval number PP-XAR-ALL-0042-1

From ROCKET AF to real-world evidence

From ROCKET AF to real-world evidence

The study assessed the safety and efficacy of rivaroxaban compared with warfarin in patients with NVAF for the prevention of stroke. These results were consistent with real-world evidence seen in prospective non-interventional studies

© Bayer AG, 2020 | Approval number PP-XAR-ALL-0097-2

When to use a reduced NOAC dose

When to use a reduced NOAC dose

Patients receiving anticoagulation with a NOAC should receive a reduced dose in certain clinical situations

© Bayer AG, 2020 | Approval number PP-XAR-ALL-1742-1

XANTUS pooled: global rivaroxaban use in real-world patients with NVAF

XANTUS pooled: global rivaroxaban use in real-world patients with NVAF

The XANTUS programme evaluated the safety and efficacy of rivaroxaban in real-world patients with NVAF across the globe

© Bayer AG, 2020 | Approval number PP-XAR-ALL-0639-1

Craig Coleman - The frail patient with NVAF

Craig Coleman - The frail patient with NVAF

Professor Craig Coleman outlines the considerations when treating frail patients with AF

© Bayer AG, 2020 | Approval number PP-XAR-ALL-0710-1

Load more

Video Categories (field_video_categories)

Videos filtered by:

Videos filtered by:

See Also

Peripheral Artery Disease: causes and consequences

See Also

Coronary Artery Disease: causes and consequences

KNOWLEDGE BASE
LATEST IN THROMBOSIS
TOOLS AND RESOURCES
THROMBOSIS ADVISER
SITEMAP

Copyright © Bayer AG |

Updated date 10/10/2022

This website is intended to provide information to an international audience outside the USA and UK.

Imprint
Privacy Statement
Conditions of Use
Report A Side Effect
Bayer Group

Copyright © Bayer AG |

Updated date 10/10/2022

This website is intended to provide information to an

international audience outside the USA and UK.

Follow us

Button

Button

Button

Button

Cookie consent image